Document:

Exhibit
10.8

 

AMENDMENT
TO ADVISORY BOARD AGREEMENT

 

This
Amendment to Advisory Board Agreement (this “Amendment”) is executed this 1st day of February, 2022 (the
“Effective Date”), by and between BIOLIFE4D, a Delaware limited liability company formerly known as BIOGEN3D Corporation
(the “Company”) and Shayn Peirce-Cottler (“Advisor”).

 

WHEREAS,
the Company and Advisor are parties to that certain Advisory Board Agreement, dated July 11, 2017 (the “Agreement”)
(all capitalized terms used herein but not otherwise defined shall have the meaning ascribed to such terms in the Agreement); and

 

WHEREAS,
the Company and Advisor desire to amend certain provisions of the Agreement as set forth in this Amendment.

 

NOW,
THEREFORE, in consideration of the provisions and undertakings set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and Advisor, intending to be legally bound, hereby agree as follows:

 

	1.	Amendment
    to Agreement. The Agreement is hereby amended as follows: Exhibit A to the Agreement is hereby deleted in its entirety
    and replaced with the Exhibit A attached hereto.
	 	 
	2.	Acknowledgments.
    The Company and Advisor hereby acknowledge and agree as follows:

 

	 	a.	The
    Company has paid all compensation due to Advisor pursuant to the Agreement for any and all services provided by Advisor to the Company
    prior to February 1, 2022; and
	 	b.	as
    of February 1, 2022, Advisor owns (i) 2,500 shares of non-voting common stock of the Company, and (ii) options to purchase 10,000
    shares of non-voting common stock of the Company.

 

	3.	Force
    and Effect of Agreement. Except as expressly modified hereby, the Agreement and all exhibits thereto are in all respects ratified
    and confirmed, and all of the terms, conditions and provisions thereof shall remain in full force and effect. This Amendment shall
    be effective upon execution and delivery by each of the parties as of the Effective Date. From and after the Effective Date, any
    reference to the Agreement, as the case may be, shall be deemed a reference to the Agreement as amended hereby.
	 	 
	4.	Governing
    Law. This Amendment will be governed by Illinois law without regards to its conflict of laws provisions.
	 	 
	5.	Counterparts.
    This Amendment may be executed in one or more counterparts, including facsimile or electronic counterparts, each of which shall be
    deemed to be an original copy of this Amendment, and all of which, when taken together, shall be deemed to constitute one and the
    same agreement. Counterparts may be delivered via facsimile, electronic mail (including PDF, .tiff or any electronic signature complying
    with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered
    shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[Signature
page follows.]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment by affixing their signatures where indicated below.

 

	COMPANY:	 	ADVISOR:
	 	 	 	 
	BIOLIFE4D
    CORPORATION	 	 
	 	 	 	 
	By:	/s/
    Steven Morris	 	/s/
    Shayn Peirce-Cottler
	Name:	Steven
    Morris	 	Shayn
    Peirce-Cottler
	Its:	Chief
    Executive Officer	 	 

 

[Signature Page to Amendment to Advisory Board Agreement]

 

    	 

     

    

 

Exhibit
A

 

“Services”:

 

Effective
as of February 1, 2022, “Services” shall be as follows:

 

	 	A.	Be
    reasonably accessible to the Company via phone and/or Zoom to provide guidance on overall strategy, laboratory setup and development,
    research strategy and techniques, research development and implementation, current lab operations and research, and other issues
    on an as needed basis.

 

“Compensation”:

 

Effective
as of January 1, 2022, “Compensation” shall be as follows:

 

The
Company shall pay Advisor $400 per hour for time spent on any formally setup phone conference or Zoom meeting in which Advisor is providing
specific research guidance to Senior Science Staff at BIOLIFE4D.Exhibit
10.9

 

ADVISORY
BOARD AGREEMENT

 

THIS
ADVISORY BOARD AGREEMENT (this “Agreement”) is entered into on August 23rd, 2017 (the “Effective
Date”) by and between BIOLIFE4D Corporation, a Delaware corporation (the “Company”), and Dr.
Jeffrey Morgan, MD (“Advisor”).

 

RECITALS

 

WHEREAS,
the Company desires to obtain the services of Advisor to serve on the Company’s Board of Advisors (the ‘‘Advisory
Board’’), and the Advisor desires to serve on the Advisory Board, upon the following terms and conditions.

 

NOW,
THEREFORE, in consideration of the foregoing recital, which is incorporated into and made a part of the Agreement, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

AGREEMENT

 

1. Advisory Board Member. The
Company hereby retains Advisor as a member of the Advisory Board, and Advisor accepts such position. Advisor also agrees to assume the
title of Chief Medical Officer. 

 

2. Term. The term of this
Agreement (the “Term”) shall be the period commencing on the Effective Date and terminating upon the later
of either (1)5 years from the Effective Date, or (2) upon immediate written notice delivered by either party to the other for any or
no reason.. 

 

3. Position, Duties, Responsibilities.

 

a.
Duties. Advisor shall perform those services (“Services”) as reasonably requested by the Company
from time to time, including but not limited to the Services described on Exhibit A attached hereto. Advisor shall make himself
reasonably available to answer questions, provide advice and provide Services to the Company upon reasonable request from the Company.

 

b.
Independent Contractor; No Conflict. It is understood and agreed, and it is the intention of the parties hereto, that Advisor is
an independent contractor, and not the employee, agent, joint venture, or partner of the Company for any purposes whatsoever. To the
extent necessary, Advisor shall be solely responsible for any and all taxes related to the receipt of any compensation under this Agreement.
Advisor hereby represents, warrants and covenants that Advisor has the right, power and authority to enter into this Agreement and that
neither the execution nor delivery of this Agreement, nor the performance of the Services by Advisor will conflict with or result in
a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which Advisor
is now or hereinafter becomes obligated.

 

c.
Company will indemnify Advisor from any losses, lawsuits, or patient- related harm that arise from the product.

 

    	 

     

    

 

4. Compensation, Benefits, Expenses.

 

a.
Compensation. As consideration for certain of the Services to be rendered by Advisor hereunder, the Company shall pay Advisor the
Compensation as defined on Exhibit A attached hereto.

 

b.
Reimbursement of Expenses. The Company shall promptly reimburse Advisor for any reasonable costs and expenses incurred by Advisor
in connection with any Services specifically requested by the Company and actually performed by Advisor pursuant to the terms of this
Agreement. Each such expenditure or cost shall be reimbursed only if: (i) with respect to costs in excess of $100, individually, Advisor
receives prior approval from the Company’s CEO or CFO or other executive for such expenditure or cost, and (ii) with respect to
costs in less than $100, individually, provided Advisor furnishes to the Company adequate records and other documents reasonably acceptable
to the Company evidencing such expenditure or cost. Company shall reimburse Advisor for any reasonable expenses incurred by Advisor in
connection with his in-person attendance at a Company board meeting, such expenses to include transportation, airline flights, hotels,
and meals.

 

5. Proprietary Information;
Work Product; Non-Disclosure.

 

a.
Proprietary Information Defined. The Company has and/or will conceive, develop and/or own, and continues to conceive and
develop, certain property and intellectual rights and information, including, but not limited to, its business plans and objectives,
products and services, client, customer and employee information, financial projections, marketing plans, marketing materials,
logos, and designs, and technical data, inventions, research, recipes, processes, know-how, marketing strategies, algorithms,
formulae, franchises, databases, computer programs, computer software and other trade secrets, information relating to patents
issued, patents pending, patent applications, trademarks, service marks, copyrights, inventions, know-how or trade secrets, or
otherwise to research and development efforts, methodologies, testing, engineering, manufacturing, sales, finances, or operations
(such as but not limited to processes, formulae, methods, designs, schematics, plans, techniques, devices, manufacturing and/or
testing procedures, sales, personnel information or data), intangible assets and industrial or proprietary property rights which may
or may not be related directly or indirectly to the Company’s business and all documentation, media or other tangible
embodiment of or relating to any of the foregoing and all proprietary rights therein of the Company (all of which are hereinafter
referred to as the “Proprietary Information”). Although certain information may be generally known in the
relevant industry, the fact that the Company uses it may not be so known. In such instance, the knowledge that the Company uses the
information would comprise Proprietary Information. Furthermore, the fact that various fragments of information or data may be
generally known in the relevant industry does not mean that the manner in which the Company combines them, and the results obtained
thereby, are known. In such instance, that would also comprise Proprietary Information.

 

    	 

     

    

 

b.
General Restrictions on Use. Advisor agrees to hold all Proprietary Information in confidence and not to, directly or indirectly,
disclose, use, copy, publish, summarize, or remove from the Company’s premises any Proprietary Information (or remove from the
premises any other property of the Company), except (i) during the Term to the extent authorized and necessary to carry out Advisor’s
responsibilities under this Agreement, and (ii) after termination of this Agreement, only as specifically authorized in writing by the
Company. Advisor shall protect the Proprietary Information against unauthorized use or disclosure with at least the same degree of care
that Advisor uses to protect its own proprietary or confidential information of a similar nature, but in no event less than a reasonable
degree of care. Notwithstanding the foregoing, such restrictions shall not apply to: (x) information which Advisor can show was rightfully
in Advisor’s possession at the time of disclosure by the Company; (y) information which Advisor can show was received from a third
party who lawfully developed the information independently of the Company or obtained such information from the Company under conditions
which did not require that it be held in confidence; or (z) information which, at the time of disclosure, is generally available to the
public.

 

The
Company may use the name of Advisor or Advisor’s affiliated university or any affiliated entity without the prior written approval
of Advisor or any affiliated entity, as the case may be, only so long as any such usage is limited to reporting factual events or circumstances
only. The Company may refer to Advisor as Chief Medical Officer. Information not requiring prior written approval of Advisor or affiliated
entity shall include but is not limited to using Advisor’s name, picture, biography and any information or videos regarding Advisor
which is public. Company may state that Advisor is a member of Company’s Advisory Board and/or is providing strategic scientific
and/or biomedical engineering advice and/or services and/or direction to Company, and may use information pertaining to Advisor for purposes
including but not limited to Company website, marketing, advertising, and fundraising.

 

c.
Ownership of Work Product. All Company Work Product (as hereinafter defined) shall be considered work(s) made for hire by
Advisor for the sole benefit of the Company and shall belong exclusively to the Company and its designees. “Company Work
Product” shall mean any and all works, ideas, inventions, improvements, discoveries, designs, writings, works of
authorship, processes, formulas, intellectual property, patents and all other documentation (whether or not patentable or
copyrightable or constituting trade secrets and whether or not reduced to writing or practice), that are authored, conceived,
developed, first reduced to practice or discovered by Advisor (whether alone or with others) (i) in the performance of the Services,
(ii) that derive from information or materials Advisor received from Company, or (iii) that relate to or result from the actual or
anticipated business, work, research or investigation of Company. All Company Work Product shall be promptly and fully disclosed by
Advisor to Company. Advisor hereby assigns all right, title and interest in and to such Work Product (including all intellectual
property embodied therein) to Company. At Company’ request and expense, Advisor shall execute, acknowledge and deliver such
assignments, declarations, certificates and other documents as Company may consider necessary or appropriate to properly evidence
Company’s right, title and interest in the Company Work Product, and all intellectual property rights embodied therein,
including, but not limited to, all copyrights and patent rights, and to obtain full protection therefor. Advisor shall execute any
and all applications for domestic and foreign patents, copyrights or other proprietary rights and do such other acts (including,
among other things, the execution and delivery of instruments of further assurance or confirmation) requested by Company to assign
the Company Work Product to Company and to permit Company to file, obtain and enforce any patents, copyrights or other
proprietary rights in the Company Work Product. Advisor’s obligation to execute, or cause to be executed, any such instrument
or paper, shall indefinitely survive the termination or expiration of Advisor’s service on the Advisory Board. All Company
Work Product and all information related thereto shall be considered Proprietary Information and shall be subject to all of the
restrictions set forth in this Agreement.

 

    	 

     

    

 

d.
Return of Proprietary Information. Upon termination of this Agreement, Advisor shall promptly deliver to the Company
all drawings, blueprints, manuals, specification documents, documentation, source or object codes, tape discs and any other storage media,
letters, notes, notebooks, reports, flowcharts, and all other materials in its possession or under its control relating to the Proprietary
Information and/or Services, as well as all other property belonging to the Company which is then in Advisor’s possession or under
its control.

 

e.
Remedies. Nothing in this Section 5 is intended to limit any remedy of the Company under applicable state or federal law.

 

6. Notice
of Competitive Services and Non-solicitation of Employees. During the Term and for 6 months thereafter, Advisor shall
provide the Company with prior written notice if Advisor intends to provide any services, as an advisor, employee, consultant or
otherwise, to any person, company or entity that competes directly with the Company, such written notice to include the name of the
competitor. Advisor agrees that during the term of this Agreement and for a period of three years thereafter, Advisor will not,
other than on behalf of or for the benefit of Company: (i) recruit or hire any employee, independent contractor or advisor of
Company, or otherwise attempt to solicit or induce any such employee, independent contractor or advisor to leave the employment of,
or terminate their relationship or provisions of services with, Company; or (ii) otherwise interfere with Company’s business
relationship with any client, vendor, independent contractor or other party with whom Company engages in business.

 

7. Miscellaneous.

 

a.
Notices. Any notice required or otherwise made pursuant to this Agreement shall be in writing, sent by registered or certified mail
properly addressed, or by email to the other party using the information set forth above or such other information as may be designated
by written notice to the other party. Notice shall be deemed effective (i) three business days following the date of sending such notice
if by mail, (ii) on the day following deposit with an overnight courier, if sent by overnight courier, (iii) upon receipt if by personal
delivery, or (iv) upon confirmation of receipt through facsimile electronic means if by email.

 

b.
Entire Agreement. This Agreement and any documents attached hereto as Exhibits constitute the entire agreement and understanding
between the parties with respect to the subject matter herein and therein, and supersede and replace any and all prior agreements and
understandings, whether oral or written with respect to such matters. The provisions of this Agreement may be waived, altered, amended
or replaced in whole or in part only upon the written consent of both parties to this Agreement.

 

    	 

     

    

 

c.
Severability, Enforcement. If, for any reason, any provision of this Agreement shall be determined
to be invalid or inoperative, the validity and effect of the other provisions herein shall not be affected thereby, provided that no
such severability shall be effective if it causes a material detriment to any party.

 

d.
Governing Law. The validity, interpretation, enforceability, and performance of this Agreement shall be governed by and construed
in accordance with the laws of the State of Illinois, and the state and federal courts located in Cook County, Illinois shall have exclusive
jurisdiction of all suits and proceedings arising out of or in connection with this Agreement. Each party hereby submits to the jurisdiction
of said courts in Cook County, Illinois for purposes of any such suit or proceeding, and waives any claim that any such forum is an inconvenient
forum.

 

e.
Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY
HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER,
(B) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY
AND (D) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN
THIS SECTION.

 

f.
Injunctive Relief. The parties agree that in the event of any breach or threatened breach of any of the covenants in Section 5 or
6, the damage or imminent damage to the value and the goodwill of the Company’s business will be irreparable and extremely difficult
to estimate, making any remedy at law or in damages inadequate. Accordingly, the parties agree that the Company shall be entitled to
injunctive relief against Advisor in the event of any breach or threatened breach of any such provisions by Advisor (without having to
post bond), in addition to any other relief (including damages) available to the Company under this Agreement or under applicable state
or federal law.

 

g.
Attorneys’ Fees. The prevailing party in any claim or litigation in connection with this Agreement shall be entitled to recover
from the non-prevailing party all costs and expenses, including, without limitation, the prevailing party’s reasonable attorneys’
and paralegals’ fees and costs in connection with any such claim or litigation.

 

h.
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be enforceable, and all of which
together shall constitute one agreement.

 

[Remainder
of page intentionally left blank.]

 

    	 

     

    

 

IN
WITNESS WHEREOF, each party hereto has duly executed this Agreement as of the Effective Date.

 

	COMPANY:
    BIOLIFE4D CORPORATION	 	ADVISOR
	 	 	 	 	 
	Signature:	/s/
    Steven Morris	 	Signature:	/s/
    Jeffrey Morgan
	 	 	 	 	 
	Print
    Name:	Steven
    Morris	 	Print
    Name:	Jeffrey
    Morgan
	 	 	 	 	 
	Title:	CEO	 	 	 

 

    	 

     

    

 

EXHIBIT
A

 

“Services”:

 

	 	●	(1)
    Participate in quarterly meetings.
	 	●	(2)
    Be reasonably accessible to the Company to provide guidance on overall strategy, laboratory setup and development, research strategy,
    research development and implementation, and other varied issues on an as-needed basis.
	 	●	(3)
    Help identify, advise on and potentially recruit potential employees, consultants, directors, advisors and other services providers
    to the Company.
	 	●	(4)
    Act in the capacity of Chief Medical Officer.
	 	●	(5)
    Provide services beyond Advisory Board services detailed above including but not limited to: assist with the design of the GLP preclinical
    studies, creation of data reports, establishment of the clinical criteria for human implantation, selection of trial sites, standardization
    of clinical protocols for implantation technique, postoperative care, and other services which are typical of Chief Medical Officer.

 

“Compensation”:

 

Company
shall: (a) pay Advisor $2,500 upon execution of this Agreement and $2,500 per 90 days until Company consummates fundraising in excess
of $5,000,000 (a “Qualified Financing”); (b) after Company consummates a Qualified Financing, pay Advisor an amount equal
to $5,000 per calendar quarter thereafter, payable within 10 days after the beginning of each such calendar quarter; (c) grant to Advisor
2,500 shares of common stock of Company (the “Grant”), which Grant shall be made within 180 days of the Effective
Date and (d) grant to Advisor 100,000 options to purchase common stock of Company at an exercise price equal to the fair market value
of such common units as of the date hereof, as reasonably determined by Company (the “Option”). The Option
shall be granted no later than 1 year following the execution of this agreement pursuant to a separate agreement containing customary
terms and conditions acceptable to Company, including, but not limited to, the following vesting schedule: (i) 50% of the Option shall
vest on the one year anniversary of the Effective Date (the “Initial Vesting Date”); and (ii) the remaining
50% of the Option shall vest on the two year anniversary of the Effective Date; (e) grant Advisor 20,000 annual options to purchase common
stock of the Company at an exercise price equal to the fair market value of such common units as of the date hereof — to be given
to advisor annually beginning on the third-year anniversary of the Effective Date and vesting 1 year later on the following year’s
anniversary; (f) as soon as Advisor, at the request of Company, begins providing the services listed in “Services”(5) above
Advisors quarterly payment shall increase from $5,000 per calendar quarter to $25,000 per calendar quarter.

 

    	 

     

    

 

BAYLOR
COLLEGE OF MEDICINE 

ADDENDUM

FOR
CONSULTING RELATIONSHIPS, ADVISORY BOARDS AND SPEAKING 

ENGAGEMENTS

 

	1.	Faculty
    and staff of Baylor College of Medicine (“BCM”) are subject to BCM’s Disclosure of Outside Interests Policy.
	 	 
	2.	It
    is required by BCM that these Uniform Provisions for Advisory Boards and Speaking Engagements (“Uniform Provisions”)
    be attached to any written agreement (“Agreement”) that will cover participation, by BCM Personnel (“Consultant”)
    who will be engaged to provide consulting services and/or serve on the Scientific or other Advisory Board of an outside entity or
    in a speaking engagement with an outside entity (“Company”), and must be signed by both parties to the Agreement. By
    signing these Uniform Provisions, the parties to the Agreement agree to abide by these Uniform Provisions, and further agree that
    if anything in the Agreement is inconsistent with these Uniform Provisions, these Uniform Provisions shall govern.
	 	 
	3.	Consultant
    may disclose to Company any information that Consultant would normally freely disclose to other members of the scientific community
    at large, whether by publication, by presentation at seminars, or in informal scientific discussions, but Consultant shall not disclose
    to Company information that is proprietary and/or confidential to BCM and is not generally available to the public (“BCM Confidential
    Information”). In the event that Consultant discloses BCM Confidential Information, the parties recognize and agree that such
    disclosure shall not be construed as granting to Company any property rights, by license or otherwise, to any BCM Confidential Information,
    or to any invention or any patent, copyright, trademark, or other intellectual property right that has issued or that may issue,
    based on BCM Confidential Information. If Consultant discloses BCM Confidential Information, the parties agree to return immediately
    all BCM Confidential Information received.
	 	 
	4.	(a)
    The Consultant shall provide scientific and medical expertise (“Services”) solely with respect to Company’s existing
    proprietary products and services or products and services in development by Company that do not conflict with the scope of Consultant’s
    professional responsibilities and/or research activities at BCM (“Field”). By signing this Addendum, The Consultant represents
    that no such conflict exists or will arise as a result of the Services provided to the Company. All services performed under the
    Agreement shall be in the Field.

 

(b)
None of the Services shall require Consultant to engage in marketing activities for Company or endorse Company’s products
and/or services. Consultant is prohibited from participation in a Company event where the overall event serves a marketing purpose,
even if the Consultant’s role is educational.

 

(c)
In performing the Services, Consultant shall not engage in the practice of medicine, function as the director or investigator of any
research efforts, or use facilities or equipment under BCM’s control.

 

    	 

     

    

 

(d)
Any photograph, logo, videotape, reproduction, likeness or image of Consultant or BCM shall not be used by Company, its affiliates,
subsidiaries or successors for recruiting, publicity, marketing, or company/product endorsement purposes. All press materials which
include Consultant’s affiliation with BCM shall be shared with The BCM Office of Communications and Marketing for review and
approval before release and shall disclose that Consultant receives financial compensation from Company. Except for
accurately describing Consultant’s affiliation with BCM, neither party shall use BCM’s name in a manner that would
identify BCM with any product or any commercial or other activity that would imply endorsement or support thereof by BCM.

 

(e)
For any presentation Consultant provides in Consultant’s performance of the Services, (i) Consultant shall have sole and complete
control over the content of the presentation as well as any materials used in connection therewith; (ii) all presentation materials shall
be substantially the work product of Consultant, except that minimal use of Company materials is permitted; and (iii) Company may review
and shall have the right to approve the presentation solely for purposes of compliance with FDA regulations. If requested by Company,
Consultant shall submit all presentations and materials for review in advance. If and when changes are made with Consultant’s approval,
and the presentation and materials are accepted by Company, Consultant shall adhere to such presentation and materials and shall not
reorganize, modify, edit, or supplement the materials except through the process as described above.

 

	5.	If
    Consultant develops any copyrightable material in Consultant’s performance of the Services (“Works”), then Consultant
    shall retain the right to use those Works not generated through the use of Company’s Confidential Information for educational
    and/or research purposes on behalf of Consultant’s employer BCM.
	 	 
	6.	Company
    acknowledges and agrees, that nothing in this Agreement shall affect the Consultant’s obligations to BCM, including, without
    limitation, the Consultant’s research activities at BCM, along with any obligations or research of the Consultant in connection
    with a transfer to a third party by BCM of materials or intellectual property developed in whole or in part by the Consultant arising
    out of Consultant’s employment by BCM, or in connection with research collaborations involving the Consultant’s BCM laboratory.
	 	 
	7.	The
    Consultant and Company acknowledge that: (i) the Consultant is entering into this Agreement in his or her individual capacity and
    not as an employee or agent of BCM, (ii) BCM is not a party to this Agreement and has no liability or obligation hereunder, and (iii)
    BCM is an intended third-party beneficiary of this Agreement and certain provisions of this Agreement are for the benefit
    of BCM and are enforceable by BCM in its own name.
	 	 
	8.	Company
    shall have no rights by reason of the Agreement in any publication, invention, discovery, improvement, or other intellectual property
    whatsoever, whether or not publishable, patentable, or copyrightable, which is developed as a result of a program of research financed,
    in whole or in part, by funds provided by, administered by, or otherwise under the control of BCM.
	 	 
	9.	Each
    party to the Agreement acknowledges that Consultant is entering into the Agreement, and providing services to Company, as an Independent
    Contractor. Consultant shall provide to BCM the terms and conditions of the Agreement, including terms for any fees payable or other
    consideration paid to or made available to Consultant by Company.

 

Company
acknowledges that Consultant is a full-time employee of BCM and agrees that, in the event the terms and conditions of the Agreement are
in conflict with the terms and conditions of Consultant’s employment by BCM, including all BCM policies and procedures, and including
the terms of any grants, contracts, funding agreements or other third party agreements administered by BCM for which Consultant performs
services, BCM policy takes precedence and shall prevail. Consultant represents that, as of the date of execution of the Agreement, no
conflicts exist with any BCM terms and conditions and that, if any arise, Consultant will promptly inform Company in writing and Company
will have the right immediately to terminate the Agreement in such event.

 

(Signature
Page Follows)

 

Acknowledged,
agreed, and confirmed:

 

	CONSULTANT	 	COMPANY
	 	 	 	 	 
	 	/s/
    Jeffrey Morgan	 	 	/s/
    Steven Morris
	 	 	 	 	 
	Name:	Jeffrey
    Morgan	 	Name:	Steven
    Morris
	 	 	 	 	 
	Date:	8/23/17	 	 Date:	 8/23/17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]